All lobbying filings

FRONTLINE GOVERNMENT RELATIONS

Lobbying for EMPOWER PHARMACY · Compounding pharmacy

Filing 2nd Quarter - Report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 15, 2026

Money reported

None

Registrations and no-activity reports carry no figure.

Client based in

Texas

Official filing document

Government bodies contacted 3

Health & Human Services, Dept of (HHS)
HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Lobbying activity 2

Health Issues

Advocated for clarity and fairness in the regulation of pharmaceutical compounding by the Food and Drug Administration (FDA), including issues related to compliance with Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.

Manufacturing

Advocated for regulatory clarity and proportional enforcement in the oversight of outsourcing facility manufacturing under Section 503B of the Federal Food, Drug, and Cosmetic Act.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.